Search

Displaying results 911 - 920 of 2250 in total
  1. Target

    Basement membrane-specific heparan sulfate proteoglycan core protein

    go.drugbank.com/bio_entities/BE0001031
    TargetHumans

    Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It se...

    Polypeptides: Basement membrane-specific heparan sulfate proteoglycan core protein
  2. Drug

    Omega-3-acid ethyl esters

    go.drugbank.com/drugs/DB09539
    ApprovedInvestigational

    Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza[FDA Label][L5849].

    Mixtures: Omega-3 Rx Complete, ROSUVASTATINA E OMEGA 3 SPA SOCIET PRODOTTI ANTIBIOTICI
  3. Drug

    Camrelizumab

    go.drugbank.com/drugs/DB14776
    Investigational

    Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

  4. Drug

    Beeswax

    go.drugbank.com/drugs/DB11600
    Approved

    The wax obtained from the honeycomb of the bee. It consists primarily of myricyl palmitate, cerotic acid esters and some high-carbon paraffins. Beeswax is used as a stiffening agent in ointments and creams, and enables water to be incorp...

  5. Drug

    Ferumoxytol

    go.drugbank.com/drugs/DB06215
    ApprovedInvestigational

    Ferumoxytol is an intravenously administered iron preparation previously indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) [

  6. Drug

    Belnacasan

    go.drugbank.com/drugs/DB05507
    Investigational

    VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). … VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.

  7. Drug

    N-acetyl-alpha-neuraminic acid

    go.drugbank.com/drugs/DB03721
    Experimental

    (From Dorland, 28th ed, p1518)

  8. Drug

    Ezogabine

    go.drugbank.com/drugs/DB04953
    ApprovedWithdrawn

    It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures

  9. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [A235000] Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization.

  10. Drug

    Sodium phosphate, monobasic

    go.drugbank.com/drugs/DB09449
    ApprovedInvestigational

    Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.

    Mixtures: E-Z Cups, AMINOPLASMAL-5% E INFUSIONProducts: FLEET ENEMA PED SOLUSYON, 66.6 ML